Evrysdi & Tagrisso Among Myriad Products To Win English Funding
Executive Summary
Roche’s oral treatment for spinal muscular atrophy and AstraZeneca’s non-small-cell lung cancer drug are among a number of medicines to get the thumbs up from the health technology assessment body, NICE.
You may also be interested in...
England Launches Innovative Medicines Fund
The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.
Roche To Work On Reversing English Funding Rejection For SMA Drug
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.